Prescription medications for use in pregnancyeperspective from the US Food and Drug Administration

被引:46
|
作者
Ren, Zhaoxia [1 ]
Bremer, Andrew A. [2 ,3 ]
Pawlyk, Aaron C. [1 ]
机构
[1] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Obstetr & Pediat Pharmacol & Therapeut Branch, Bethesda, MD 20892 USA
[2] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Growth & Nutr Branch, Bethesda, MD USA
[3] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pregnancy & Perinatol Branch, Bethesda, MD USA
关键词
17-hydroxyprogesterone caproate; Cervidil; Diclegis; dinoprostone; doxyl-amine; drug approval in pregnancy; drugs approved for use in pregnancy; FDA; FDA guidance; FDA regulations; FDA review of drugs; Makena; magnesium sulfate; Meth-ergine; methylergonovine maleate; oxytocin; Pitocin; Prepidil; pyridoxine; ritodrine; Syntocinon; Yutopar; 17-ALPHA-HYDROXYPROGESTERONE CAPROATE; QUANTITATIVE-DETERMINATION; PREGNANT PATIENTS; NIFEDIPINE PHARMACOKINETICS; TRANSPLACENTAL TRANSFER; PLACENTAL MICROSOMES; GLYBURIDE METABOLISM; MASS-SPECTROMETRY; MATERNAL PLASMA; WOMEN;
D O I
10.1016/j.ajog.2021.04.227
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Obstetrical healthcare providers frequently field questions about the safety of medications recommended or prescribed to their pregnant patients. Most women use as least 1 medication during pregnancy; however, there is little information about the safety or appropriate dosing of many medications during this phase of life. In addition, the development of drugs for use in pregnant women trails behind the development of drugs intended for other sectors of the population. Our goal is to inform the obstetrics community about the US Food and Drug Administration authority and their role in approving drugs for marketing. We begin with the statutes that led to the creation of the Food and Drug Administration and its current organization. We then cover drug development and the Food and Drug Administration review process, including the role of the advisory committee. The different types of drug approvals are discussed, with some specific examples. Finally, we enumerate the drugs specifically approved for use in obstetrics and contrast them with drugs commonly used by pregnant women and drugs used "off-label" during pregnancy. The Food and Drug Administration is committed to protecting and advancing the public health of pregnant women by guiding the development and ensuring the availability of effective and safe therapeutics for obstetrical indications and for medical conditions during pregnancy. We hope this review will inspire more research addressing drug use during pregnancy.
引用
收藏
页码:33 / 42
页数:10
相关论文
共 50 条
  • [21] Key Evidence Supporting Prescription Opioids Approved by the US Food and Drug Administration, 1997 to 2018
    Heyward, James
    Moore, Thomas J.
    Chen, Jennifer
    Meek, Kristin
    Lurie, Peter
    Alexander, G. Caleb
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (12) : 956 - +
  • [22] Integrated Drug Reviews at the US Food and Drug Administration
    Woodcock, Janet
    Stein, Peter
    Bugin, Kevin
    JAMA INTERNAL MEDICINE, 2020, 180 (09) : 1248 - 1250
  • [23] Prescription Drug Advertising and Promotion: Learnings from Recent Food and Drug Administration Warning Letters
    Eric B. Benson
    Sherman N. Alfors
    Drug information journal : DIJ / Drug Information Association, 2007, 41 : 281 - 289
  • [24] Prescription drug advertising and promotion: Learnings from recent food and drug administration warning letters
    Benson, Eric B.
    Alfors, Sherman N.
    DRUG INFORMATION JOURNAL, 2007, 41 (03): : 281 - 289
  • [25] Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014
    Rathi, Vinay K.
    Wang, Bo
    Ross, Joseph S.
    Downing, Nicholas S.
    Kesselheim, Aaron S.
    Gray, Stacey T.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2017, 156 (04) : 683 - 692
  • [27] US Food and Drug Administration Efforts to Facilitate the Use of Expanded Access Programs
    Kim, Tamy
    Lurie, Peter
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) : 3979 - +
  • [28] US Food and Drug Administration defends use of placebo-controlled trials
    Larkin, M
    LANCET, 2000, 356 (9235): : 1086 - 1086
  • [29] Varenicline and Nicotine Replacement Use Associated With US Food and Drug Administration Drug Safety Communications
    Desai, Ravi J.
    Good, Meghan M.
    San-Juan-Rodriguez, Alvaro
    Henriksen, Andrew
    Cunningham, Francesca
    Hernandez, Inmaculada
    Good, Chester B.
    JAMA NETWORK OPEN, 2019, 2 (09)
  • [30] Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications
    Chua, Kao-Ping
    Conti, Rena M.
    JAMA NETWORK OPEN, 2021, 4 (11)